Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum IGC Pharma Inc IGC

Healthcare Cannabis
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its... see more

NYSEAM:IGC - Post Discussion

IGC Pharma Inc > InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Re
View:
Post by whytestocks on Sep 18, 2024 6:17pm

InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Re

News; $IGC InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer'sIGC Pharma (NYSE American: IGC) , an AI-powered, clinical-stage biotechnology company, today announced data that supports the therapeutic potential of IGC-AD1 as a disease modifying treatment for Alzheimer’s. According to the announcement, findings from studies have shown that IGC-AD1 has ...IGC - InvestorNewsBreaks - IGC Pharma Inc. (NYSE American: IGC) Reports Data Showing IGC-AD1's Potential to Effectively Target Tau Pathology, Improve Cognitive Function in Alzheimer's
Be the first to comment on this post
IGC Pharma Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities